Chemistry:Tipelukast

From HandWiki
Tipelukast
Tipelukast.svg
Names
IUPAC name
4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenyl)sulfanylpropoxy]-2-propylphenoxy]butanoic acid
Other names
KCA 757; MN-001
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
DrugBank
KEGG
UNII
Properties
C29H38O7S
Molar mass 530.68 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Tipelukast (KCA 757 or MN-001) is a sulfidopeptide leukotriene receptor antagonist with suspected anti-inflammatory properties. It is developed by MediciniNova.[1][2][3][4]

References

  1. "MN-001 - MediciNova, Inc.". https://medicinova.com/clinical-development/core/mn-001-nash/. 
  2. Rajasekaran, Mahadevan; Locke, Kenneth W.; Parsons, C. Lowell (August 2006). "MN‐001, a novel oral anti‐inflammatory agent, suppresses bladder hyperactivity in a rat model". BJU International 98 (2): 430–434. doi:10.1111/j.1464-410X.2006.06274.x. PMID 16879690. 
  3. Matsuda, Kazuko; Iwaki, Yuichi (December 2014). "MN-001 (tipelukast), a novel, orally bioavailable drug, reduces fibrosis and inflammation and down-regulates TIMP-1, collagen Type 1 and LOXL2 mRNA overexpression in an advanced NASH (nonalcoholic steatohepatitis) model: LB-28". Hepatology 60 (6): 1283A. ISSN 0270-9139. https://journals.lww.com/hep/citation/2014/12000/mn_001__tipelukast_,_a_novel,_orally_bioavailable.76.aspx. 
  4. Bascom, R.; Hitz, K.; Dimmock, A.E.F.; Makhay, M.; Dojillo, J.; Matsuda, K. (May 2020). "Description of Protocol to Evaluate MN-001'S (tipelukast) Efficacy, Safety and Tolerability in Subjects with Idiopathic Pulmonary Fibrosis". A37. Ild Therapy I. pp. A1493. doi:10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A1493.